In Vivo and In Vitro Anticancer Activity of Doxorubicin-loaded DNA-AuNP Nanocarrier for the Ovarian Cancer Treatment
Open accessAbstract
In this study, we have determined the anticancer activity of doxorubicin (Dox)-loaded DNA/gold nanoparticle (AuNP) nanocarrier (Dox-DNA-AuNP) for the treatment of ovarian cancer. The anticancer effect of Dox-DNA-AuNP was evaluated in vitro using the EZ-Cytox cell viability assay on three human ovarian cancer cell lines, SK-OV-3, HEY A8, and A2780. Dox-DNA-AuNP exhibited outstanding activity with good IC50 values of 4.8, 7.4, and 7.6 nM for SK-OV-3, HEY A8, and A2780, respectively. In vivo evaluation further demonstrated the superior anticancer effects of Dox-DNA-AuNP by inhibiting tumor growth compared to free Dox in an established SK-OV-3 xenograft mice model. Dox-DNA-AuNP showed about a 2.5 times higher tumor growth inhibition rate than free Dox. Furthermore, the immunohistochemical analysis of Ki67 antigen expression showed the lowest number of proliferative cells in the ovarian tumor tissue treated with Dox-DNA-AuNP. These results suggest Dox-DNA-AuNP might be a potential effective agent in ovarian cancer chemotherapy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Monolayer systems fall short in predicting in vivo therapeutic efficacy despite their utility in mechanistic studies and target validation.
“However, despite their utility in mechanistic studies and target validation, these models fall short in predicting in vivo therapeutic efficacy.”
From Modeling Tumor Microenvironment Complexity In Vitro: Spheroids as Physiologically Relevant Tumor Models and Strategies for Their Analysis (2025) · cites this paper as [170]
The Methods (§3.6) describe in vitro cell-viability tests, and the Results (§2.5) report therapeutic effects in mice. Searches for monolayer models, mechanistic studies, target validation, and prediction of in vivo efficacy found no passage assessing whether monolayer systems can predict those effects. (LLM, conf=0.73)
Experimental — accuracy not yet measuredNumerous anticancer compounds that demonstrate robust activity in monolayer cultures fail to reproduce such outcomes in vivo.
“Numerous anticancer compounds that demonstrate robust activity in monolayer cultures fail to reproduce such outcomes in vivo [168,169,170,171].”
From Modeling Tumor Microenvironment Complexity In Vitro: Spheroids as Physiologically Relevant Tumor Models and Strategies for Their Analysis (2025) · cites this paper as [170]
Sections 2.4 and 2.5 examine one doxorubicin nanocarrier in cultured ovarian cancer cells and in mice; they report anticancer activity in vivo. Neither section addresses whether numerous compounds active in monolayer cultures fail to reproduce those results in vivo. Searches for that comparison and for monolayer-culture limitations found no supporting passage in our copy. (LLM, conf=0.75)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233 · see citing works
Colorectal cancer statistics, 2017
Siegel, R. L., Miller, K. D., Fedewa, S. A., Ahnen, D. J., Meester, R. G. S., Barzi, A., & Jemal, A. (2017) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21395 · Cited by 3,807 · see citing works
Determination of Size and Concentration of Gold Nanoparticles from UV−Vis Spectra
Haiss, W., Thanh, N. T. K., Aveyard, J., & Fernig, D. G. (2007) · Analytical Chemistry · doi:10.1021/ac0702084 · Cited by 3,685 · see citing works
Epidemiology of ovarian cancer: a review
Reid Brett, M., Reid Brett, M., Permuth, J. B., Sellers Thomas, A., Permuth, J. B., & Sellers Thomas, A. (2017) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2016.0084 · Cited by 1,592 · see citing works
Acidic extracellular microenvironment and cancer
Kato, Y., Ozawa, S., Miyamoto, C., Maehata, Y., Suzuki, A., Maeda, T., & Baba, Y. (2013) · Cancer Cell International · doi:10.1186/1475-2867-13-89 · Cited by 1,295 · see citing works
Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy
Palmerston Mendes, L., Pan, J., & Torchilin, V. (2017) · Molecules · doi:10.3390/molecules22091401 · Cited by 701 · see citing works
Rapid Aggregation of Gold Nanoparticles Induced by Non-Cross-Linking DNA Hybridization
Sato, K., Hosokawa, K., & Maeda, M. (2003) · Journal of the American Chemical Society · doi:10.1021/ja034876s · Cited by 663 · see citing works
Nanotherapeutics to Overcome Conventional Cancer Chemotherapy Limitations
Chidambaram, M., Manavalan, R., & Kathiresan, K. (2011) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j30c7d · Cited by 576 · see citing works
Drug Resistance and Cellular Adaptation to Tumor Acidic pH Microenvironment
Wojtkowiak, J. W., Verduzco, D., Schramm, K. J., & Gillies, R. J. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200292c · Cited by 568 · see citing works
Application of gold nanoparticles in biomedical and drug delivery
Daraee, H., Eatemadi, A., Abbasi, E., Aval, S. F., Kouhi, M., & Akbarzadeh, A. (2014) · Artificial Cells Nanomedicine and Biotechnology · doi:10.3109/21691401.2014.955107 · Cited by 545 · see citing works
Manzoor, A. A., Lindner, L. H., Landon, C. D., Park, J. Y., Simnick, A. J., Dreher, M. R., Das, S. K., Hanna, G., Park, W., Chilkoti, A., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1683 · Cited by 461 · see citing works
Dauthal, P., & Mukhopadhyay, M. (2016) · Industrial & Engineering Chemistry Research · doi:10.1021/acs.iecr.6b00861 · Cited by 447 · see citing works
Mesoporous Silica Nanoparticles as Drug Delivery Vehicles in Cancer
Watermann, A., & Brieger, J. (2017) · Nanomaterials · doi:10.3390/nano7070189 · Cited by 404 · see citing works
Yao, C., Wang, P., Li, X., Hu, X., Hou, J., Wang, L., & Zhang, F. (2016) · Advanced Materials · doi:10.1002/adma.201503799 · Cited by 344 · see citing works
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2009) · Co-Published with Macmillan Publishers Ltd, UK eBooks · doi:10.1142/9789814287005_0025 · Cited by 324 · see citing works
Chitosan-based nanoparticles as drug delivery systems for doxorubicin: Optimization and modelling
Soares, P. I. P., Sousa, A. I., Silva, J. A. M. D. C., et al. (2016) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2016.03.028 · Cited by 194 · see citing works
Doxorubicin-loaded platelets as a smart drug delivery system: An improved therapy for lymphoma
Xu, P., Zuo, H., Chen, B., et al. (2017) · Scientific Reports · doi:10.1038/srep42632 · Cited by 173 · see citing works
Zhao, X., Wei, Z., Zhao, Z., Miao, Y., Qiu, Y., Yang, W., Jia, X., Liu, Z., & Hou, H. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b16910 · Cited by 168 · see citing works
Mirrahimi, M., Abed, Z., Beik, J., Shiri, I., Dezfuli, A. S., Mahabadi, V. P., Kamrava, S. K., Ghaznavi, H., & Shakeri‐Zadeh, A. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.005 · Cited by 166 · see citing works
Mahdavi, M., Rahmani, F., & Nouranian, S. (2016) · Journal of Materials Chemistry B · doi:10.1039/c6tb00746e · Cited by 165 · see citing works
Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism
Li, S., Ma, J., & Wong, A. S. T. (2018) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2018.29.e32 · Cited by 148 · see citing works
Safwat, M. A., Soliman, G. M., Sayed, D. M., & Attia, M. A. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00047 · Cited by 138 · see citing works
Zhang, M., Zhu, J., Zheng, Y. F., Guo, R., Wang, S., Mignani, S. M., Caminade, A., Majoral, J., & Shi, X. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10030162 · Cited by 129 · see citing works
Synthesis and Evaluation of Doxorubicin-Loaded Gold Nanoparticles for Tumor-Targeted Drug Delivery
Du, Y., Xia, L., Jo, A., Davis, R. M., Bissel, P., Ehrich, M. F., & Kingston, D. G. I. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00756 · Cited by 127 · see citing works
Lee, C., Kim, H., Yu, J., Yu, S., Ban, S., Oh, S., Jeong, D., Im, J., Baek, M. J., & Kim, T. H. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.063 · Cited by 106 · see citing works
Self-citationZhu, J., Wang, G., Alves, C. S., Tomás, H., Xiong, Z., Shen, M., Rodrigues, J., & Shi, X. (2018) · Langmuir · doi:10.1021/acs.langmuir.8b02901 · Cited by 95 · see citing works
Fernandes, A. R., de Jesus, J. T. C. L., Martins, P. H. D. F., Figueiredo, S., Rosa, D., Martins, L. M. D. R. S., Corvo, M. L., Carvalheiro, M. C., Costa, P. M., & Baptista, P. V. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.021 · Cited by 81 · see citing works
Aval, N. A., Islamian, J. P., Hatamian, M., Arabfirouzjaei, M., Javadpour, J., & Rashidi, M. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.05.046 · Cited by 80 · see citing works
Carvalho, S. M., Leonel, A. G., Mansur, A. A. P., Carvalho, I. C., Krambrock, K., & Mansur, H. S. (2019) · Biomaterials Science · doi:10.1039/c8bm01528g · Cited by 80 · see citing works
Golshan, M., Salami‐Kalajahi, M., Roghani‐Mamaqani, H., et al. (2017) · Polymer · doi:10.1016/j.polymer.2017.04.047 · Cited by 74 · see citing works
Hu, W. S., Qiu, L., Cheng, L., Hu, Q., Liu, Y., Hu, Z., Chen, D., & Cheng, L. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.03.027 · Cited by 73 · see citing works
Zhang, Y., Wang, C., Wang, H., et al. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.01.022 · Cited by 62 · see citing works
Kotcherlakota, R., Srinivasan, D. J., Mukherjee, S., et al. (2017) · Journal of Materials Chemistry B · doi:10.1039/c7tb01587a · Cited by 53 · see citing works
Song, S., Hao, Y., Yang, X., et al. (2016) · Journal of Nanoscience and Nanotechnology · doi:10.1166/jnn.2016.12349 · Cited by 44 · see citing works
Wen, X., Yang, F., Ke, Q., et al. (2017) · Journal of Materials Chemistry B · doi:10.1039/c7tb01830d · Cited by 42 · see citing works
Kohay, H., Sarısözen, C., Sawant, R. R., Jhaveri, A. M., Torchilin, V. P., & Mishael, Y. G. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.04.008 · Cited by 38 · see citing works
Xia, B., Zhang, Q., Shi, J., et al. (2018) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2018.01.059 · Cited by 38 · see citing works
Effect of BN Nanoparticles Loaded with Doxorubicin on Tumor Cells with Multiple Drug Resistance
Zhitnyak, I. Y., Bychkov, I., Sukhorukova, I. V., et al. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b08713 · Cited by 35 · see citing works
Pegylated liposomal doxorubicin in the management of ovarian cancer
Ferrandina, G. (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3348 · Cited by 31 · see citing works
de Miguel, D., Gallego-Lleyda, A., Martinez-Ara, M., et al. (2019) · Cancers · doi:10.3390/cancers11121948 · Cited by 19 · see citing works
Kim, J. A., Yoon, D. Y., & Kim, J. (2020) · Cancers · doi:10.3390/cancers12010180 · Cited by 15 · see citing works
Mita, S., Nakai, A., Maeda, S., et al. (2004) · Journal of Nippon Medical School · doi:10.1272/jnms.71.384 · Cited by 13 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [42]Cree I.A. Cancer Cell Culture: Methods and Protocols Humana Press Totowa, NJ, USA 2016 978-1-4939-5657-9
Cited by
Sorted by citations
Shah, S., & D’Souza, G. G. M. (2025) · Cells · doi:10.3390/cells14100732 · Cited by 66 · see citing works
- Authors
- Lee, C.-S., Kim, T., Oh, D., Bae, S., Ryu, J., Kong, H., Jeon, H., Seo, H., Jeon, S., & Kim, T.
- Affiliations
- Soonchunhyang University (KR)
- Department of Medical Life Science, Soonchunhyang University, Asan 31538, Korea
- Department of Obstetrics and Gynecology, College of Medicine, Soonchunhyang University Cheonan Hospital, Cheonan 31151, Korea
- Corresponding author
- Jeon, Seob
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2020-03-09
- Volume
- 12
- Issue
- 3
- Pages
- 634
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC7139456
- OpenAlex
- W3010160178
- Cited by
- 46
- References
- 42
- Citations by year
- 2026: 6 · 2025: 13 · 2024: 8 · 2023: 6 · 2022: 6 · 2021: 6 · 2019: 1
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Korea Environmental Industry and Technology Institute (2019002800001)
- Soonchunhyang University (000000000)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Electronic, Optical and Magnetic Materials › Gold and Silver Nanoparticles Synthesis and Applications
- Keywords
- doxorubicin, ovarian cancer, drug delivery, nanoparticle drug delivery, tumor growth inhibition, Ki-67 proliferation index, SKOV3 cells, A2780 cells, xenograft tumor model, chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
